Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

摘要: Abstract Background An increasing number of patients are presenting with peritoneal carcinomatosis and more centers performing cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC). While morbidity mortality shown to be acceptable, quality life after should assessed. Methods 63 who had CRS HIPEC from 2001 2012 were still alive on follow up included. The EORTC-QLQ-C30 was administered the patients. Results Median age 53 years (14–71). 44% ovarian primaries, 21% appendicael primaries 19% colorectal primaries. follow-up 1.08 (0.06–9.8). median time questionnaire 1.3 (0.24–10.18). There no statistical difference in scores when comparing by age, gender, recurrence, PCI score, presence a complication type primary cancer. Scores highest less than 6 months surgery, dropped subsequently but rose again 2 years. Our better compared control group outpatient cancer at our institution as well reference EORTC group. Conclusions In keeping previous studies done for patients, we have that can achieve good even recurrent disease.